Stocks Raising Investors Eye Brows: Citigroup Inc. (NYSE:C), UBS Group AG (NYSE:UBS)

Citigroup Inc. (NYSE:C) persists its position slightly strong in context of buying side, while shares price eased up 0.68% during latest trading session.  It’s something you don’t see very often: a major global bank admitting guilt. But this week, that’s what we got with Citigroup. A three-year investigation wrapped up, resulting in $22.5 million being reimbursed to thousands of the New York-based bank’s consumers.

Citigroup, through one of its subsidiaries, had overcharged more than 47,000 of its consumers with fees. This week, Attorney General Eric Schneiderman reported a resolution to the four-year investigation. As a part of the contract, Citigroup admits the findings of the investigation and revised its policies and procedures to address the fee overcharge issues.

“Our investigation put $22.5 million rightfully back in the hands of consumers in New York and across the country,” Schneiderman said. “We appreciate Citi’s cooperation with our investigation and its commitment to ensuring investors are paid back what they are owed — which sets an example for other financial institutions.”

Analysts Practices; to watch unbiased undervalue securities, there is need to see following technical rations. C holds price to earnings ratio of 12.86 that presents much better indication for a stock’s value than the market price alone. Based on historic views, the average P/E ratio in market fluctuates between 15 to 25, but alone low P/E ratio does not necessarily mean that a company is undervalued. With reference to all theories, earning yield also gives right direction to lure investment, as C has 1.07% dividend yield.  In addition, the firm has debt to equity ratio of 0.88, sometimes its remain same with long term debt to equity ratio.

UBS Group AG (NYSE:UBS) also run on active notice, stock price ascend 2.34% after traded at $17.06 in most recent trading session.

UBS has price to earnings ratio of 18.79 and the price to current year EPS stands at 80.10%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 19.11%. The earning yield also gives right direction to lure investment, as the co has 4.89% dividend yield. The debt to equity ratio appeared as 1.42 for seeing its liquidity position.

Taking notice on volatility measures, price volatility of stock was 1.50% for a week and 1.29% for a month. The price volatility’s Average True Range for 14 days was 0.35. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 4.00 out of 1-5 scale with week’s performance of 1.67%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *